Compare L3Harris Technologies Inc (LHX) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? L3Harris Technologies Inc trades at $236.8 (market cap $44.12B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| LHX | RPRX | |
|---|---|---|
Market Cap | $44.12B | $25.27B |
Volume | 1,202,852 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $378.48 | $63.96 |
52-Week Low | $233.63 | $35.44 |
Typical Hold Time | 56 Days | 1 Days |
Enterprise Value | $54.56B | $32.50B |
Dividend Yield | 2.11% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.97, up 1.43% today, with a bearish technical signal despite strong fundamentals. The company reported revenue of $21.87B in 2025, with net income of $1.61B and improving profit margins. Recent contract wins, including a $6B THAAD propulsion deal with Lockheed Martin, highlight growth prospects. However, multiple law firm investigations into the company have emerged in September 2026, creating investor uncertainty.
The outlook is mixed: analyst consensus is bullish with a $340 price target, but technical indicators and legal overhangs pose risks. Earnings beats in recent quarters support fundamental strength, yet sentiment is tempered by bearish momentum and potential legal liabilities. Upside depends on contract execution and resolution of investigations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
